Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Zynex Inc reports strong Q3 performance and eyes growth opportunities

Zynex Inc's Q3 2024 performance reflects revenue growth, profitability, and strategic reinvestment in the business.
While facing challenges in decision-making and operational efficiency, the company is well-positioned for growth.
Opportunities in expanding sales, launching new products, and exploring partnerships pave the way for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Zynex, Inc. (ZYXI) CEO Thomas Sandgaard on Q3 2019 Results - Earnings Call Transcript

The company basks in device orders growing at 30% sequentially and 95% y/y.

Zynex Breaks Out With The Flywheel Effect Yet To Come

Zynex (ZYXI) is likely to maintain the current high on a number of favorable factors.

Zynex (ZYXI) Scales 52-Week High: What's Driving the Stock?

Stars Group

Sibanye-Stillwater

On a terrible day for the market, these stocks fought against the tide.

Why Stars Group, Sibanye Gold, and Zynex Jumped Today

A moderate sales force expansion provides a path to $400M in revenue per year.

Modeling The Zynex Income Statement Shows A Compelling Opportunity

President, CEO and Chairman of Zynex Inc (30-Year Financial, Insider Trades) Thomas Sandgaard (insider trades) sold 131,260 shares of ZYXI on 08/19/2019 at an average price of $10.58 a share.

Zynex Inc (ZYXI) President, CEO and Chairman Thomas Sandgaard Sold $1.4 million of Shares

Canadian Solar

HUYA Inc - ADR

Inmode Ltd

These four stocks have strong technical momentum aligning with upbeat earnings.

4 Stocks Breaking Out After Earnings

Considering the company's history (especially pre-2015), investors had reason to be concerned Zynex (ZYXI) would not be able to seize the extraordinary opportunity presented by the exit of its competitors in the electrotherapy pain management market.

Zynex: More Bullish Developments For This Fast-Growing Company

Zynex's (ZYXI) CEO Thomas Sandgaard on Q2 2019 Results - Earnings Call Transcript

The company produced stellar Q2 figures despite a rather epic sales force ramp that took S&M 111% higher in the quarter.

Bull Thesis In Zynex Confirmed By Q2 Figures

Zynex is one of the only major players in a small niche, the electro-therapy market.

I Am A Bearish Bull On Zynex; It's Complicated

Conagra Brands

Patterson Companies

Find out what left these companies out of the rally.

Why Conagra Brands, Patterson Companies, and Zynex Slumped Today

The medical device company sprouts SaaS-like metrics; 30%+ growth, 80% recurring revenues, 80%+ gross margin and it's profitable and cash flow positive.

The Zynex Party Has Much Further To Go

Biosig Technologies Inc

Coda Octopus Group

Everbridge

GW Pharmaceuticals

Rent-A-Center

Despite May's large losses, these stocks to buy made new 52-week highs. Maybe this is a signal that they will continue to head higher.

7 Stocks to Buy That Are Near 52-Week Highs

Zynex's (ZYXI) CEO Thomas Sandgaard on Q1 2019 Results - Earnings Call Transcript

Zynex’s main competitors have shut down, leaving the company with the sole quality electrotherapy device for pain management.

Zynex: Uncontested Market Leader In Electrotherapy Pain Management, An Opioid Alternative

ZYXI is gaining market share in huge addressable markets.

News for Zynex Inc Stock (ZYXI)